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Summary objective To facilitate the choice of the best visceral leishmaniasis (VL) treatment strategy for ﬁrst-line
health services in (VL)-endemic areas, we compared in a formal decision analysis the cost and the cost-
effectiveness of the different available options.
methods We selected four drug regimens for VL on the basis of frequency of use, feasibility and
reported efﬁcacy studies. The point estimates and the range of plausible values of effectiveness and cost
were retrieved from a literature review. A decision tree was constructed and the strategy minimizing the
cost per death averted was selected.
results Treatment with amphotericin B deoxycholate was the most effective approach in the baseline
analysis and averted 87.2% of all deaths attributable to VL. The least expensive and the most cost-
effective treatment was the miltefosine regimen, and the most expensive and the least cost-effective was
AmBisome
  treatment. The cost of drug and medical care are the main determinants of the cost-
effectiveness ranking of the alternative schemes. Sensitivity analysis showed that antimonial was com-
petitive with miltefosine in the low-resistance regions.
conclusion In areas with >94% response rates to antimonials, generic sodium stibogluconate remains
the most cost-effective option for VL treatment, mainly due to low drug cost. In other regions, miltef-
osine is the most cost-effective option of treatment, but its use as a ﬁrst-line drug is limited by its
teratogenicity and rapid resistance development. AmBisome in mono- or combination therapy is too
expensive to compete in cost-effectiveness with the other regimens.
keywords visceral leishmaniasis, drug policy, cost-effectiveness analysis
Introduction
Visceral leishmaniasis (VL), a fatal disease if left untreated,
affects mainly people of the lowest socioeconomic status in
developing countries who have minimal power to inﬂuence
the political agenda and a very limited capacity to assume
the costs of the disease (Desjeux 1996). Clinical cases of VL
suffer from prolonged fever, anaemia, weakness, spleno-
megaly and, to a lesser extent, lymphadenopathy and
malaise. At the advanced stage, wasting is prominent, but
once a patient responds well to treatment, disability is
averted. The World Health Organization (WHO) estimates
the incidence of VL at 500 000 new cases per year (UNDP/
World Bank/WHO Special Programme for Research and
Training in Tropical Diseases 1997), half of which are
occurring in India (Jha et al. 1998). The global ﬁgure does
not reﬂect the real importance of VL in affected commu-
nities, because VL has a focal distribution. Reported
incidence rates of kala-azar in endemic areas vary between
2/1000 person-years in Kenya (Schaefer et al. 1995),
14/1000 person-years in Ethiopia (Ali & Ashford 1994)
and 40/1000 person-years in a community in eastern Sudan
(Zijlstra et al. 1994). Despite the considerable burden,
there has been little attempt to quantify the economic
consequences of the disease in these communities. Adhikari
and Maskay (2003) estimated that the total cost of a kala-
azar episode for a household in Nepal may be as much as
US$ 210, which is 2.5 times an average annual per capita
household income (US$ 82). Thakur (2000) related that
75% of VL patients in Bihar, India, lived below the poverty
threshold of less than US$ 1 income per capita per day.
This seriously compromises the prognosis of VL, because in
some countries patients have to pay for diagnostics, drugs
and hospital care out of their own pockets. Other coun-
tries, such as Nepal, provide the drugs free of charge to
conﬁrmed VL patients through public health services.
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the diseases ‘most neglected’ by drug research and
development, as there is a lack of effective, affordable
and easy-to-use drugs (Yamey & Torreele 2002; Morel
2003). The WHO-recommended treatment regimen is a
30-day course of antimonials (intramuscular or intra-
venous), which, for an average 35-kg patient, costs
between US$ 120 and 150 per course in the branded
version (Glucantime
  or Pentostam
 ) to US$ 28 per
course in the generic version (stibogluconate) (Sundar
et al. 2000a; Murray 2001). Griekspoor et al. (1999)
estimated the cost-effectiveness ratio of VL care based on
Pentostam in a relief programme in Sudan at US$ 18.40
per disability adjusted life year (DALY) averted, and
judged it as ‘very good value for money’ and among the
most cost-effective health interventions. Antimonials are
not an ideal drug; they have to be administered
parenterally over a period of 28–30 days, generally
requiring hospitalization. Antimonials have shown rare
but serious side effects, such as cardio, pancreas and
liver toxicity (Gasser et al. 1994; Sundar et al. 1998c;
Thakur et al. 1998; Rijal et al. 2003), whose importance
increases if the patient is coinfected with HIV (Delgado
et al. 1999; Laguna et al. 1999). Resistance to antimo-
nials has been reported in up to 65% of patients in some
villages of Bihar, India (Sundar 2001). In these areas, the
current ﬁrst-line treatment is amphotericin B deoxycho-
late. AmBisome
  (a lipid formulation of amphotericin B)
is recommended in most endemic countries as the
second-line therapy, but is unaffordable for most patients
(US$ 1747 per course for a person weighing 35 kg).
Recently, a number of breakthroughs in VL chemother-
apy have occurred: adoption of generic antimonials for VL
control in East Africa (Veeken et al. 2000); clinical
development of miltefosine as the ﬁrst oral drug for VL
(Sundar et al. 1998b, 2002a), which can be used safely in
children (Sundar et al. 2003; Bhattacharya et al. 2004);
development of low-cost lipid formulations of amphoter-
icin B (Sundar et al. 2000a). Paromomycin phase III trials
are in progress in India (Institute for One World Health)
and East Africa (Drugs for Neglected Diseases initiative),
and pharmaceutical manufacture has recently been secured
(Thakur et al. 2000a; Croft & Coombs 2003).
The most important strategy for anthroponotic VL
control is case detection and treatment (Boelaert et al.
2000), because no vaccine is available and vector control
has limited efﬁcacy and sustainability. If less complex and
safer drug regimens could be adopted, more effective VL
control could be achieved.
In this paper, we compared in a formal decision analysis
the costs and the cost-effectiveness of the different actually
available options for VL treatment in ﬁrst-line health
services in endemic areas, in order to facilitate the choice of
the best strategy.
Methods
Clinical decision analysis is a quantitative method for
evaluating the consequences of alternative strategies and
permits the choice of the most effective or most cost-
effective course of action in complex situations. The
method requires the following:
• a decision tree describing possible alternative strat-
egies;
• information on the probabilities attached to the events
in each strategy and
• a judgement about the clinical and economic conse-
quences of each intervention (Weinstein & Fineberg
1980).
We tried to answer the following question: what is the
most cost-effective drug regimen in the management of VL
in ﬁrst-line health services in endemic regions?
Therapeutic strategies
We decided to compare the following four regimens,
selected on the basis of frequency of use, feasibility and
reported efﬁcacy (Table 1).
Strategy A is the WHO-recommended one, antimo-
nials (generic or branded version) 20 mg/kg/day
intramuscularly for 30 days. In some countries, the
duration of treatment is 28 days or/and the regimen is
administered intravenously.
Strategy B is the Indian ﬁrst-line regimen based on
amphotericin B deoxycholate, 15 infusions of 1 mg/kg
on alternate days.
Strategy C is the only existing oral treatment regimen,
miltefosine 2.5 mg/kg/day, for 28 days.
Strategy D is a regimen of a lipid formulation of
amphotericin B (liposomal amphotericin B or AmB-
isome, amphotericin B lipid complex) 2 mg/kg/day for
ﬁve consecutive days, a frequently used second-line
scheme in endemic areas (A variety of dosing schemes
has been tested, ranging from single infusion up to
10 days treatment, with total dosages from 5 up to
20 mg/kg).
Decision tree structure
We constructed a decision tree to compare these strategies
(Figure 1), taking a patient presenting with clinical
signs and symptoms of VL as the starting point. After
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patients, the branches of the decision tree lead to the
following outcomes.
• ‘VL – treated’, i.e. a real case of VL is correctly
diagnosed and treated accordingly.
• ‘Erroneously treated’, i.e. a person without VL is
incorrectly diagnosed as VL and wrongly receives
treatment for a disease he/she does not have.
• ‘VL – untreated’, i.e. a real case of VL is missed
because of a false-negative test result and conse-
quently, the VL case is not treated.
• ‘Correctly ruled out’, i.e. a person without VL in
whom the disease is correctly ruled out and therefore
does not receive treatment for VL.
Probabilities, effectiveness and cost assumptions
Table 1 shows the baseline probability estimates used in
the decision analysis. A literature review (Medline search
accessed between January 2004 and August 2004) provi-
ded a range of plausible values for those parameters about
which uncertainty exists. In the absence of pooled esti-
mates from systematic reviews of all endemic regions
worldwide, we took the result of the clinical trial with the
highest power as the baseline point estimate for effective-
ness, and included the other effectiveness estimates in the
range subjected to sensitivity analysis.
Effectiveness. The marginal health beneﬁts or losses of a
strategy and its utility, i.e. the patient’s perceptions of
the quality of life associated with a health state, were
disregarded, and overall effectiveness was expressed as
deaths averted relative to mortality in the absence of
intervention. However, it should be noted that sequelae
of VL do occur, as up to 50% of initially cured kala-
azar patients can develop post-kala-azar dermal
leishmaniasis (PKDL), a non-life-threatening
dermatological complication which is difﬁcult to cure
and is considered to be a reservoir of transmission, as
PKDL cases are highly infectious (Zijlstra et al. 2003).
As the differential impact of the available treatments on
the appearance of PKDL is not yet studied, we
disregarded this sequel in our study.
Table 1 Effectiveness and cost estimates of currently available chemotherapy against VL in immunocompetent patients
Drug Regimen
Total
dose
(MK)
Effectiveness
(%) (range)
Drug cost
(US$) (range)
Care cost
(US$) (range) References
Antimonials 20 MKD for
30 days IM
600 92 (36–96) 28 (28–149) 143 (143–420) Seaman et al. (1993),
Griekspoor et al. (1999),
Murray (2000, 2001),
Sundar et al. (2000a),
Veeken et al. (2000),
Thakur et al. (2000b),
Ritmeijer et al. (2001)
Amphotericin B
deoxycholate
1 MKD, 15
infusions on
alternate days
15 97 (96–99) 69 (69–255) 279 (279–416) Sundar et al. (1997, 2001,
2002a, 2004), Thakur et al. (1999),
Murray (2000)
Miltefosine 2.5 MKD,
per os,
28 days
70 94 (88–94) 140 (70§–198) 40 (40–480) Sundar et al. (2002a, 2003),
Bhattacharya et al. (2004)
Lipid
formulation of
amphotericin B
(AmBisome
 ,
Abelcet
 )
2 MKD,
5 days
10 92 (90–96) 1120 (455– –4138) 90 (90–111) Sundar et al. (1997, 2000a, 2004),
Murray (2000)
5 MK,
single
infusion
5 91 (70–91) 560 (230–658) 42 Sundar et al. (1998a, 2001)
Various
regimens
5–20 (78–100) (230–4138) (90–102) Sundar et al. (1997, 1998a,
2001, 2002b, 2004), Murray (2000),
Syriopoulou et al. (2003)
Values used in baseline analysis are given in bold. Range of plausible values between parentheses. MK, mg/kg; MKD, mg/kg/day.
Effectiveness estimated as proportion cases with negative parasitology/no clinical signs at the end of 6-month follow-up period.
All drug cost values computed for a 35-kg patient.
§Purchase via Acteon Medeor, Germany.
–Public sector price for Africa only.
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signs and symptoms of VL (prolonged fever and spleno-
megaly). For the baseline analysis, we assumed that the
diagnostic test used was the rK39 dipstick, as proposed by
Chappuis et al. (2006) with a sensitivity of 90.1% [95%
conﬁdence interval (CI): 85.7–94.6] and a speciﬁcity of
93.1% (95% CI: 87.5–98.6) (Boelaert et al. 2004), and
that every rK39-positive individual was subsequently
treated. We evaluated the robustness of our conclusions by
changing the values of sensitivity and speciﬁcity of rK39 to
the lowest (85.7% for sensitivity and 87.5% for speciﬁcity)
and highest (respectively 94.6% and 98.6%) values of the
above-mentioned 95% CI.
We derived the effectiveness value of a true-positive
diagnosis (treating a true case of VL) directly from the
efﬁcacy estimates of the drug obtained in clinical trials,
evaluated at 6 months interval after the start of treatment.
As fatal toxicity of a drug is already reﬂected in the efﬁcacy
ﬁgures of randomized controlled trials, we did not have to
add toxicity estimates to this outcome. We assigned an
effectiveness value of 0 to a false-negative diagnosis
(i.e. a missed diagnosis of a true case of VL), as the
eventual outcome, death, would be the same as when the
disease was allowed to follow its natural course. We also
assigned an effectiveness of 0 to a true-negative diagnosis
(the correct ruling out of VL), because it does not directly
avert deaths (although it may off-course lead to psycholo-
gical beneﬁt in such patients). A false-positive diagnosis
exposes a person to a relatively toxic treatment, and
therefore we considered the effectiveness of a false-positive
outcome as (0 – toxicity of drug). Moreover, it delays
correct diagnosis and any other potentially life-saving
treatment, but this was disregarded in the valuation of this
outcome. Data on serious adverse events in healthy people
in ﬁeld contexts are very scarce for the drugs we studied.
For the iatrogenic death rate of antimonials, we used the
same estimate as Boelaert et al. (1999) at 1 death per 1000
healthy individuals treated. It has been demonstrated in
India that the case–fatality rate is signiﬁcantly higher in VL
patients treated with antimonials than in those treated with
an alternative drug (Thakur 2004). This gives an indication
that also in healthy individuals, the toxicity could be much
higher than the estimate of 0.001; therefore, we put the
range up to 0.07 deaths/treatment, which was the ﬁgure
found by Sundar et al. (2000b) in a cohort of VL patients
under antimonial treatment. For the other drugs, we used
information from drug trials. The toxicity of miltefosine is
estimated at 0.0003 deaths/treatment based on the occur-
rence of Stevens–Johnson syndrome in one patient among
299 treatments with miltefosine (Sundar et al. 2002a),
which has a mortality of 1–15% (Schopf et al. 1991;
Ghislain & Roujeau 2002). The toxicity of amphotericin
B deoxycholate has been estimated at 0.003 deaths/
treatment by Thakur et al. (1999), and according to the
FDA, there is comparative safety information on
amphotericin B deoxycholate and lipid formulations of
amphotericin B (Meyerhoff 1999). Olliaro et al. (2005)
reported more frequent (mostly minor) adverse events
during treatment with amphotericin B deoxycholate, and
we included a range up to 0.01 deaths/treatment in the
sensitivity analysis.
Costs. The total cost of VL care for one patient comprises
the cost of the diagnostic test, the speciﬁc anti-leishmanial
drug, the cost of possible retreatment episodes, ancillary
drugsandpatientcareduringthetreatmentcourseuntilcure
was obtained. We estimated the cost of rK39 dipstick at
US$1/test(Chappuiset al.2006).Thepointestimatesofthe
drug costs are computed for an ‘average’ 35-kg patient and
were provided by the Campaign for Access to Essential
Medicines of ‘Me ´decins Sans Frontie `res’ in March 2006.
The costs of care are based on the prices in the treatment
centres, as published elsewhere (Table 1) (Meyerhoff 1999;
Murray 2000, 2001; Boelaert et al. 2002). Unit costs were
adjusted for inﬂation to year 2004 prices, using the Indian
consumer price index (the last year for which the consumer
price indices were available at the time of this study).
(Source: Indian Central Statistical Ofﬁce; http://
labourbureau.nic.in/cpi%20iw%202004%20table%
204%20p.htm, accessed 7 August 2006).
Figure 1 Decision tree.
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the literature. For retreatment, we assumed that AmB-
isome
 , 3 mg/kg/day, for 5 days would be given as second-
line treatment to every failure in the ﬁrst-line treatment
(Sundar et al. 2000a). Cost of this regimen is estimated at
US$ 1747 for a 35-kg patient, care included (Murray 2000;
Sundar et al. 2000a).
The costs of patient care incurred under the different
regimens are presented from the perspective of the health
service, as in most countries the government subsidizes the
VL case management. Information on cost of patient care
is scarce and highly variable depending on the context. In
this study, our data were based on initial cost estimations
of Sundar and Murray from previous studies in India
(Murray 2000; Sundar et al. 2000a). Cost of patient care
included: cost of hospitalization day [baseline estimate US$
4 (range 2–100)], ancillary drugs and adjuvant treatment
for the side effects of the chosen strategy, injection material
and – fee, routine laboratory and other complementary
tests and fees for medical doctor visits.
The duration of hospital admission depends on the
strategy. In endemic countries, patients treated by anti-
monials are generally admitted for 1 week, and continue
injections on an ambulatory basis afterwards. We assumed
that miltefosine, as it is an oral drug with side effects that
last for 1–2 days (Sundar et al. 2002a), would only need a
mean of 2 days of inpatient care to supervise possible
adverse reactions of the patient to the drug. Amphotericin
B deoxycholate gives a lot of side effects that persist in
63% of the cases even at the 10th infusion (day 20)
(Sundar et al. 2004) and needs a good hydration of the
patient; therefore ambulatory treatment is excluded. The
AmBisome
  regimen studied here requires infusions during
5 days, which we counted as the period of hospitalization.
Analysis
We analysed efﬁciency from the perspective of the health
service and used the patient consulting with signs and
symptoms for VL as starting point to address the question
of most efﬁcient therapeutic approach. The expected
effectiveness of each strategy was estimated by calculating
the sum of the effectiveness values of each possible
outcome of the strategy weighted by their probability of
occurring. The strategy averting most deaths was consid-
ered to be the most effective. A cost-effectiveness analysis
was then performed and the strategy minimizing the cost
per death averted was considered the most cost-effective
therapeutic strategy.
Subsequently, one-way and two-way sensitivity analyses
were performed on those parameters of probability and
cost that were subject to appreciable uncertainty: cost and
efﬁcacy of drugs, sensitivity and speciﬁcity of the diag-
nostic test, toxicity, care and hospitalization costs. The
analysis was performed using data
TM v.3.0 software
(TreeAge, Williamstown, MA, USA).
Results
Cost, effectiveness and cost-effectiveness of the different
strategies
Table 1 shows that the reported efﬁcacy of regimens does
not differ much, ranging between 91% (lipid formulation
of amphotericin B, single infusion) and 97% (amphotericin
B deoxycholate). Treatment with amphotericin B
deoxycholate is the most effective approach in the baseline
analysis. This strategy averts 349 deaths per 1000 clinical
suspects enrolled, or 87.2% of all deaths attributable to
VL in a group of clinical suspects with a prior probability
of 0.40 of having the disease (Table 2). Miltefosine
treatment ranks second, followed by antimonials
(in antimonial-sensitive regions) and AmBisome
  with
comparable effectiveness (avoiding 83–84% of VL deaths).
The cost of the four strategies (taking into account
effectiveness, toxicity and retreatment need) ranged from
US$ 111.1 to 537.5 per clinical suspect enrolled. The least
expensive treatment strategy is the most recently intro-
Table 2 Comparison of the cost, effectiveness and cost-effectiveness ratio of the different therapeutic strategies in baseline analysis
Strategy
Cost (US$
per clinical
suspect
enrolled)
Effectiveness
(deaths averted
per 1000
clinical suspects)
Cost-effectiveness
(US$/death averted)
Marginal cost-effectiveness ratio
(US$/death averted)
Antimonials (SSG) 120.1 332 362.2 Dominated by miltefosine strategy
Miltefosine 111.1 339 327.9 Dominant strategy
Amphotericin B deoxycholate 159.7 349 457.0 4543.3
AmBisome
  537.5 331 1621.8 Dominated by amphotericin B deoxycholate
Strategies ranked by increasing cost and best-ranked values are given in bold.
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the AmBisome
  treatment scheme. If we use the point
estimates of Table 1, the most cost-effective scheme is the
miltefosine strategy with a cost of US$ 327.9 per death
averted. There is a striking contrast between the ﬁrst
three strategies (A, B and C) with a range of US$
327.9–457.0 per death averted and the US$ 1621.8 per
death averted for the lipid formulations of amphotericin B
(AmBisome
 ) strategy. We observe that cost is the main
determinant in this cost-effectiveness comparison as the
range of effectiveness is quite narrow, but prices of drugs
and cost of care are very divergent.
The cost of care is mainly determined by the supportive
treatment and the different medical and laboratory exam-
inations necessary for all strategies (73–77% of total care
cost) except for amphotericin B, where the hospitalization
days are responsible for just over 50% of the care costs.
Incremental costs
We compared miltefosine treatment with the amphotericin
B deoxycholate regimen, which is the only more effective
one, to determine the incremental cost to save an
additional life, which elevates to US$ 4543.3 per death
averted.
Sensitivity analysis
When allowing for changes, respectively, in the efﬁcacy of
antimonials (>93.9%) (Figure 2), as well as in the drug
efﬁcacy (<92.5%), in the drug cost (>US$ 168.9), and cost
of medical care (>US$ 68.9) of miltefosine, all within the
range found in literature, antimonials become competitive
with the miltefosine strategy. The AmBisome
  strategy
approaches the cost and cost-effectiveness of amphotericin
B deoxycholate treatment only when the preferential
pricing that is currently available to the public sector in
Africa, is applied together with a single infusion regimen of
5 mg/kg total dose.
A sensitivity analysis for the other variables in the
model did not lead to a different choice of the most cost-
effective strategy. There were only changes in the
ranking of cost-effectiveness of the different regimens.
When the drug price of antimonials rises to US$ 100 per
course, amphotericin B deoxycholate becomes the most
cost-effective treatment after miltefosine.
The sensitivity analysis on the cost of a hospitalization
day did not change the choice of most cost-effective
strategy, as miltefosine does not require long hospitaliza-
tion. When the hospitalization day price rises to US$ 50,
amphotericin B deoxycholate treatment becomes less cost-
effective than AmBisome
  treatment.
The conclusions on cost-effectiveness were also robust
when changing the sensitivity and speciﬁcity of the
diagnostic test to lower values. We observed slight differ-
ences in effectiveness and cost, showing among others, that
more sensitivity leads to strategies with higher effectiveness
but also higher cost, because of more true patients to treat.
Discussion
Cure rates of the currently available ﬁrst-line drug
regimens for VL are high and range between 91% and
97%, except in Bihar State in India, where antimonials
cure less than 50% of the patients. However, the drug cost
of those different regimens varies between US$ 28 and
1120 per average treatment course and this is, together
with the cost of patient care, the main determinant for
the efﬁciency of a therapeutic strategy. In our analysis, in
areas with a certain level of drug resistance patterns to
antimonials, a miltefosine-based strategy is the most cost-
effective at US$ 328 per death averted. Miltefosine has a
cure rate of 94%, requires a short hospitalization period as
it is an oral drug, gives few major side effects and has a
balanced price (in comparison with the alternative regi-
mens). In areas where antimonials remain highly effective,
with cure rates above 93.9% antimonials compete with
miltefosine and are in the same range of cost-effectiveness.
Amphotericin B deoxycholate is the most effective
drug, but because of its prolonged hospitalization
requirement, it becomes slightly less cost-effective than
the ﬁrst two options. AmBisome
 -based treatment is not
competitive with the other regimens because of its current
high drug cost. Even at the preferential pricing for the
Figure 2 Sensitivity analysis on efﬁcacy antimonials. *US$/death
averted.
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course is almost double the price of the other regimens.
The question whether miltefosine is a valid substitute for
the antimonials is not easy to answer. Antimonials are
problematic drugs because of their toxicity and need for
parenteral administration. The painful injections and long
hospitalization period add to the burden from the patient’s
perspective. Miltefosine has the clear advantage of oral
administration, and this is more than an issue of patient
comfort and cost. Singh et al. (2000) pointed out the risk
of transmitting blood-borne infections such as HIV,
Hepatitis B and C, with parenteral treatment of VL because
of unsafe injection practices. The main disadvantage is the
potential teratogenicity of this drug, which complicates its
use as ﬁrst-line treatment for women of reproductive age.
Non-supervised treatment with this drug may leave VL
patients with sub-therapeutic doses, and this, given its long
half-life, implies a high risk of development of resistance.
Moreover, the ﬁgures of the cure rates used in this analysis
came from controlled clinical trials and we have to be
careful with their extrapolation to effectiveness, as irregu-
lar intake of drugs and interruption of treatment are likely
in real life.
Is AmBisome
  a realistic alternative for the ﬁrst-line
health services, regardless of its cost? The answer is not
straightforward because of regional variation of its effect-
iveness. In Brazil, the regimen studied (2 mg/kg during
5 days) was insufﬁcient, and a total dose of 20 mg/kg was
needed to attain the acceptable effectiveness (Berman et al.
1998). The FDA recommends a total dose of 21 mg/kg,
given on 7 days over a 21-day period (Meyerhoff 1999).
The lack of sufﬁciently powered clinical trials of shorter
regimens compared with the standard FDA regimen and
the huge variety of dosage schemes reported (from
3.75 mg/kg total dose to 30 mg/kg total dose and from
single infusion up to 21 days of treatment) make any
therapeutic recommendation on shorter regimens difﬁcult.
An equivalence or non-inferiority study could bring guid-
ance in the best choice of regimen and the minimal dose
needed.
In countries with high hospitalization costs, such as the
Leishmania infantum endemic areas in the Mediterranean
basin, any approach that reduces hospital stay can offset
the cost of expensive drugs. Pagliano et al. (2003)
reported in Italy that the cost of AmBisome
  3 mg/kg/day
given on an inpatient basis during ﬁve consecutive days
with a sixth dose on day 10 (at € 4100), compared
favourably to the € 4200 for a 21-day inpatient course of
meglumine antimoniate (Glucantime
 ). Similarly, in
Greece, where cost of hospitalization was € 88 per day,
the total cost of short regimens of AmBisome
  compared
favourably to that of inpatient treatment with
Glucantime
  (Syriopoulou et al. 2003). However, one
should remember that, from the patient’s perspective, the
AmBisome
  and miltefosine regimens present advantages
that were not taken into account in our analysis, as a
shorter time period of loss of income for both the diseased
persons and their attendants.
How useful are the results of cost-effectiveness analysis
when it comes to the formulation of drug policy recom-
mendations? The conclusions of this analysis are applicable
in all VL endemic regions, on condition that the point
estimates of effectiveness and cost are comparable to local
ﬁgures. The decision analytic model used as the basis for
the cost-effectiveness analysis is a simple one-period model,
which does not capture longer term beneﬁts and risks of
treatment strategies. The main beneﬁt, impact on trans-
mission, and the main risk, drug pressure with the
probability of subsequent resistance development, are not
well-studied subjects and therefore difﬁcult to take into
account in an analysis. Moreover, if the emergence of drug
resistance is to be prevented, monotherapies should be
avoided, and combination therapies have to be considered.
In our analysis, we saw that the drug price is the main
determinantintherankingofcost-effectivenessinthetypical
Leishmania donovani areas, where hospitalization is relat-
ively cheap. From the viewpoint of the cost issues, antimo-
nials,miltefosineandamphotericinBdeoxycholatearevalid
candidates to insert in combination therapies, but the
inclusion of AmBisome
 , even if it was a single dose, would
raise the price of treatment to unacceptable levels.
In L. infantum areas, where hospitalization is relatively
expensive, antimonials and amphotericin B deoxycholate
are not very attractive drugs for combination therapies
unless the duration of treatment is considerably
shortened.
Croft (2001) and Bryceson (2001) proposed a combi-
nation therapy of sodium stibogluconate and paromo-
mycin. Paromomycin monotherapy, applicated
parenterally during 21 days, showed promising efﬁcacy
results in Phase II trials and could become a valuable
alternative treatment in the future because of its low
price and relatively low toxicity (Jha et al. 1998; Thakur
et al. 2000a).
Another factor to be taken into consideration when
making therapeutic recommendations is the emergence of
HIV–Leishmania coinfection. These patients present more
serious and frequent side effects than patients infected only
with Leishmania (Delgado et al. 1999). Their response to
treatment is also poor: antimonials, amphotericin B deo-
xycholate and amphotericin B lipid complex are showing
an effectiveness of around 60–70% (Laguna 2003), and
similar ﬁgures have been reported for miltefosine (Sinder-
mann et al. 2004).
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of the treatment of this highly lethal disease that affects
mainly the poorest, but also to adequately use and protect
the few existing drugs, as there are no other new drugs in
the pipeline of the pharmaceutical industry. Meanwhile,
price reductions of lipid formulations of amphotericin B
would relieve a bottleneck in the treatment of kala-azar
patients.
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Politique des me ´dicaments contre la leishmaniose visce ´rale: une analyse de cou ˆt efﬁcacite ´
objectif Pour faciliter le choix de la meilleure strate ´gie de traitement de la leishmaniose viscerale (LV) dans les services de sante ´ de 1 ere ligne dans des
zones ende ´miques nous avons compare ´ dans une analyse formelle de de ´cision le cou ˆt et le cou ˆt-efﬁcacite ´ de diffe ´rentes options disponibles.
me ´thode Nous avons choisi quatre re ´gimes de me ´dicaments contre la LV sur base de la fre ´quence d’utilisation, la faisabilite ´ et les e ´tudes d’efﬁcacite ´
rapporte ´es. L’estimation ponctuelle et l’amplitude des valeurs plausibles de l’efﬁcacite ´ et du cou ˆt ont e ´te ´ tire ´s d’une revue de litte ´rature. Un arbre de
de ´cision a e ´te ´ construit et la strate ´gie re ´duisant au minimum le cou ˆt par de ´ce `se ´vite ´ ae ´te ´ choisie.
re ´sultats Le traitement au de ´soxycholate d’amphote ´ricine B e ´tait l’approche la plus efﬁcace dans l’analyse de ligne de base en e ´vitant 87,2% de tous
les de ´ce `s attribuables a ` la LV. Le traitement le moins cher et le plus cou ˆt-efﬁcace e ´tait celui au Miltefosine et le plus cher et moins cou ˆt-efﬁcace e ´tait celui
a ` l’AmBisome
 . Le cou ˆtd um e ´dicament et des soins me ´dicaux e ´tait le de ´terminant principal dans le classement de cou ˆt-efﬁcacite ´ des sche ´mas alternatifs.
L’analyse de sensibilite ´ ad e ´montre ´ que les antimonie ´s  etaient en compe ´tition avec le Miltefosine dans les zones de re ´sistance basse.
conclusion Dans les zones avec des taux de re ´ponse >94% aux antimonios, le ge ´ne ´rique de stibogluconate sodique demeure l’option la plus rentable
pour le traitement de la LV, principalement due au faible cou ˆtd um e ´dicament. Dans d’autres zones, le miltefosine constitue l’option de traitement la plus
cou ˆt-efﬁcace, mais son utilisation comme me ´dicament de 1 ere ligne est limite ´e par sa te ´ratoge ´nicite ´ et le de ´veloppement rapide de re ´sistance. L’AmB-
isome
  en monothe ´rapie ou en combinaison est trop cou ˆteux pour concurrencer les autres traitements en terme de cou ˆt efﬁcacite ´.
mots cle ´s leishmaniose visce ´rale, politique sur les me ´dicaments, analyse de la rentabilite ´, analyse de cou ˆt-efﬁcacite ´
Polı ´tica de medicamentos para la Leishmaniasis Visceral: ana ´lisis de costo-efectividad
objetivo Con el ﬁn de facilitar la eleccio ´n de la estrategia de tratamiento de leishmaniasis visceral ma ´s adecuada para los servicios sanitarios de
primera lı ´nea en a ´reas ende ´micas, hemos comparado en un ana ´lisis formal de decisiones el costo y la costo-efectividad de las diferentes opciones
disponibles.
me ´todo Hemos seleccionado cuatro regimenes de medicamentos para la LV, basa ´ndonos en la frecuencia de uso, la viabilidad y los estudios de eﬁcacia
publicados. Los estimaciones puntuales y el rango de valores plausibles de costos y efﬁcacia se basaron en una revisio ´n bibliogra ´ﬁca. Se construyo ´ un
a ´rbol de decisio ´n y se selecciono ´ la estrategia que minimizaba el costo por muerte evitada.
resultados El tratamiento con desoxicolato de Amfotericina B era la estrategia ma ´s efectivo en el ana ´lisis basal y prevenı ´a un 87.2% de todas las
muertes atribuibles a LV. El tratamiento ma ´s barato y costo-efectivo era el re ´gimen con Miltefosine, mientras que el ma ´s costoso y menos costo-efectivo
era aquel con AmBisome
 . El costo de los medicamentos y tratamiento me ´dico son los principales determinantes del rango de costo-efectividad de las
diferentes estrategias. Los ana ´lisis de sensibilidad mostraban que el antimonial era competitivo con Miltefosine en las regiones con baja resistencia.
conclusio ´n En a ´reas con tasas de respuesta a antimoniales de >94%, el estibogluconato so ´dico gene ´rico continu ´a siendo la opcio ´nm a ´s costo-efectiva
para el tratamiento de la LV, principalmente debido al bajo costo del medicamento. En otras regiones, Miltefosine es la opcio ´n de tratamiento ma ´s
costo-efectiva, pero su uso como primera lı ´nea de tratamiento es limitada por su teratogenicidad y el ra ´pido desarrollo de resistencias. El AmBisome
 ,
bien en mono-dosis o como terapia de combinacio ´n, es demasiado costoso para competir desde un punto de vista de costo-efectividad con otros
regı ´menes.
palabras clave leishmaniasis visceral, polı ´tica de medicamentos, ana ´lisis de costo-efectividad
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